Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trazodone in major affective disorders.

J P Feighner

    Psychopathology
    |January 1, 1984
    PubMed
    Summary

    Trazodone is an effective antidepressant for major depressive disorders, well-tolerated by most patients. It is a preferred choice when standard tricyclic antidepressants cause undesirable atropine side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers.

    Biopharmaceutics & drug disposition·2005
    Same author

    Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression.

    International clinical psychopharmacology·2001
    Same author

    Citalopram treatment of fluoxetine nonresponders.

    The Journal of clinical psychiatry·2001
    Same author

    A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.

    Journal of affective disorders·2000
    Same author

    Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

    The Journal of clinical psychiatry·2000
    Same author

    Overview of antidepressants currently used to treat anxiety disorders.

    The Journal of clinical psychiatry·2000

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology

    Background:

    • Major depressive disorder (MDD) treatment often involves tricyclic antidepressants (TCAs).
    • TCAs can present significant atropine-related side effects, limiting their use.
    • Alternative antidepressants with better tolerability are needed.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of trazodone.
    • To assess trazodone as an alternative to TCAs in MDD.

    Main Methods:

    • Conducted inpatient and outpatient double-blind control trials.
    • Gathered open-label experience with trazodone treatment.

    Main Results:

    • Trazodone demonstrated broad-spectrum antidepressant efficacy.
    • The drug was generally well tolerated by the majority of patients.
    • Trazodone offers an alternative when TCA side effects are contraindicated.

    Conclusions:

    • Trazodone is an effective and well-tolerated option for major depressive disorders.
    • It is a recommended alternative for patients experiencing adverse atropine effects from TCAs.

    Related Experiment Videos